Harnessing nanoparticles to improve toxicity after head and neck radiation

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue 7, 2012, Pages 1223-1231

  Madero Visbal, Rafael A ^a   Alvarado, Beatrice E ^a   Colon, Jimmie F ^a   Baker, Cheryl H ^d   Wason, Melissa S ^a   Isley, Beth ^a   Seal, Sudipta ^b,c   Lee, Chris M ^a   Das, Soumen ^b,c   Mañon, Rafael ^a  

^a M D ANDERSON CANCER CENTER ORLANDO   (United States)

^b University of Central Florida   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA   (United States)

^d UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Cerium oxide nanoparticles; Nanoparticle; Radiation induced toxicity; Radioprotection; Radiotherapy; Xerostomia

Indexed keywords

CERIUM OXIDE NANOPARTICLE; CERIUM OXIDES; HEAD AND NECK; HYPERPIGMENTATION; MOUSE MODELS; RADIATION TREATMENTS; RADIATION-INDUCED; RADIATION-INDUCED TOXICITY; RADIOPROTECTION; SALIVARY FLOW; X-RAY SYSTEM; XEROSTOMIA;

CERIUM COMPOUNDS; MAMMALS; NANOPARTICLES; OXIDES; RADIOTHERAPY; TOXICITY;

RADIATION;

CERIUM OXIDE; CERIUM OXIDE NANOPARTICLE; NANOPARTICLE; RADIOPROTECTIVE AGENT; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; FEMALE; HEAD AND NECK RADIATION; HYPERPIGMENTATION; IRRADIATION; MOUSE; NONHUMAN; RADIATION DERMATITIS; RADIATION DOSE; RADIATION PROTECTION; RADIATION RESPONSE; RADIOTHERAPY; SALIVARY GLAND DISEASE; SALIVARY GLAND FUNCTION; SALIVATION; XEROSTOMIA;

ANIMALS; CERIUM; DERMATITIS; FEMALE; HEAD AND NECK NEOPLASMS; MICE; MICE, NUDE; NANOPARTICLES; RADIOTHERAPY; SKIN; XEROSTOMIA;

MUS;

EID: 84866524453     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2011.12.011     Document Type: Article

References (31)

1. Chao K.S. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002, 12(1 Suppl 1):20-25.
2. Eisbruch A., Kim H.M., Terrell J.E., Marsh L.H., Dawson L.A., Ship J.A. Xerostomia and its predictors following parotid-sparing irradiation of head-and-neck cancer. Int J Radiat Oncol Biol, Phys 2001, 50:695-704.
3. Rosenthal D.I. Established and emerging uses of cytoprotection in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132:129-130.
4. Rosenthal D.I., Lewin J.S., Eisbruch A. Prevention and treatment of dysphagia and aspiration after chemoradiation for head and neck cancer. J Clin Oncol 2006, 24:2636-2643.
5. Dormand E.L., Banwell P.E., Goodacre T.E. Radiotherapy and wound healing. Int Wound J 2005, 2:112-127.
6. Eisbruch A., Marsh L.H., Martel M.K., Ship J.A., Ten Haken R., Pu A.T., et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. Intern J Radiat Oncol, Biol, Phys 1998, 41:559-568.
7. Eisbruch A. Reducing xerostomia by IMRT: what may, and may not, be achieved. J Clin Oncol: Off J Am Soc Clin Oncol 2007, 25:4863-4864.
8. Eisbruch A., Levendag P.C., Feng F.Y., Teguh D., Lyden T., Schmitz P.I., et al. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences. Int J Radiat Oncol Biol Phys 2007, 69(2 Suppl):S40-S42.
9. Kam M.K., Leung S.F., Zee B., Suen J.J., Mo F., Lai M., et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007, 25:4873-4879.
10. Citrin D., Cotrim A.P., Hyodo F., Baum B.J., Krishna M.C., Mitchell J.B., et al. Radioprotectors and mitigators of radiation-induced normal tissue injury. Oncologist 2010, 15:360-371.
11. Braaksma M., van Agthoven M., Nijdam W., Uyi-de Groot C., Levendag P., et al. Costs of treatment intensification for head and neck cancer: concomitant chemoradiation randomised for radioprotection with amifostine. Eur J Cancer 2005, 41:2102-2111.
12. Rades D., Fehlauer, Bajrovic A., Mahlmann B., Richter E., Alberti W., et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 2004, 70:261-264.
13. Tarnuzzer R.W., Colon J., Patil S., Seal S. Vacancy engineered ceria nanostructures for protection from radiation-induced cellular damage. Nano Lett 2005, 5:2573-2577.
14. Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009, 27:127-145.
15. Brizel D.M., Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 2006, 24:2612-2617.
16. Brizel D.M., Overgaard J. Does amifostine have a role in chemoradiation treatment?. Lancet Oncol 2003, 4:378-381.
17. Brunner T.J., et al. In vitro cytotoxicity of oxide nanoparticles: comparison to asbestos, silica, and the effect of particle solubility. Env Sci Technol 2006, 40:4374-4381.
18. Chen J., Patil S., Seal S., McGinnis J.F. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides. Nature Nanotechnol 2006, 1:142-150.
19. Das K.K., Gupta A.D., Dhundasi S.A., Patil A.M., Das S.N., Ambekar J.G., et al. Protective role of L-ascorbic acid on antioxidant defense system in erythrocytes of albino rats exposed to nickel sulfate. Biometals 2007, 20:177-184.
20. Rzigalinski B.A. Nanoparticles and cell longevity. Technol Cancer Res Treat 2005, 4:651-659.
21. Rzigalinski B.A. Radical nanomedicine. Nanomedicine 2006, 1:399-412.
22. Patil A.J. Occupational lead exposure in battery manufacturing workers, silver jewelry workers, and spray painters in western Maharashtra (India): effect on liver and kidney function. J Basic Clin Physiol Pharm 2007, 18:87-100.
23. Colon J., Hsieh N., Ferguson A., Kupelian P., Seal S., Jenkins W., et al. Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. Nanomedicine 2010, 6:698-705.
24. Colon J., Herrera L., Smith J., Patil S., Komanski C., Kupelian P., et al. Protection from radiation-induced pneumonitis using cerium oxide nanoparticles. Nanomedicine 2009, 5:225-231.
25. Hirst S.M., Karakoti A.S., Tyler R.D., Sriranganathan N., Seal S., Reilly C.M., et al. Anti-inflammatory properties of cerium oxide nanoparticles. Small 2009, 5:2848-2856.
26. Hall E.J. Time dose and fractionation in radiotherapy. A comparison of two evaluation systems in clinical use. Br J Radiol 1969, 42:427-431.
27. Brizel D.M., Wasserman T.H., Henke D.M., Trnad V., Rudat V., Monnier A., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000, 18:3339-3345.
28. Li Y., Ten Haken R.K., Eisbruch A. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 2007, 67:660-669.
29. Park E.J., Chooi J., Park Y.K., Park K. Oxidative stress induced by cerium oxide nanoparticles in cultured BEAS-2B cells. Toxicology 2008, 245:90-100.
30. Dawson L.A., Anzai Y., Marsh L., Martel M.K., Paulino A., Ship J.A., et al. Patterns of local-regional recurrence following parotid-sparing conformal and segmental intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol 2000, 46:1117-1126.
31. Ask A., Bjork-Eriksson T., Zackrisson B., Blomquist E., Glimelius B. The potential of proton beam radiation therapy in head and neck cancer. Acta Oncol 2005, 44:876-880.